Company intelligence / Profile preview

CSPC NBP Pharmaceutical

Shijiazhuang, Hebei, Chinaen.e-cspc.com ↗
Ownership
Private
Development stage
Other
01

Overview

The company’s flagship product "dl‑3‑n‑Butylphthalide" ("NBP") leads the global market for stroke management. It has treated over 10 million patients since launch. The drug has orphan drug designation from the FDA and is in Phase III trials in the US. The company also produces a range of small molecules and biologics targeting CNS disorders, oncology indications such as myelosuppression support during chemotherapy ("Jinyouli"), anti-infectives and cardiovascular disease. Several biosimilars are approved or under development.

Therapeutic areas
ImmunologyCardiovascular
Modalities
Small moleculeMonoclonal antibodyAntibody-drug conjugateBiosimilarBispecific antibody
Industry
Pharma
02

Drug pipeline

5 assets

toll-like receptor agonist liposome

Preclinical

4 more assets in the full pipeline.

03

Partnerships

Harbour BioMed – exclusive rights transfer agreement for batoclimab/HBM9161 development/commercialization in Greater China region.Verastem Oncology – licensing agreement for COPIKTRA®(duvelisib) oral PI3K inhibitor.Other collaborations with academic institutions not specified by name.

Beyond the preview

Go deeper on CSPC NBP Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSPC NBP Pharmaceutical.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call